Poor Outcome of Pediatric Patients with Acute Myeloid Leukemia Harboring High FLT3/ITD Allelic Ratios

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Jun 27

PMID 35760968

Authors

Kun-Yin Qiu

Xiong-Yu Liao

Yong Liu

Ke Huang

Yang Li

Jian-Pei Fang

Dun-Hua Zhou

Affiliations

Soon will be listed here.

Abstract

Activating FLT3 mutations are the most common mutations in acute myeloid leukemia (AML), but the optimal threshold of FLT3/ITD allelic ratio (AR) among pediatric AML patients remains controversial. Here, we present the outcome and prognostic significance of FLT3/ITD AR analysis among pediatric patients with AML from the TARGET dataset. Applying fitting curve models and threshold effect analysis using the restrictive cubic spline function following Cox proportional hazards models identifies the cut-off value of 0.5 on FLT3/ITD AR. Moreover, we observe that high FLT3/ITD AR patients have an inferior outcome when compared to low AR patients. Our study also demonstrates that stem cell transplantation may improve the outcome in pediatric AML patients with high FLT3/ITD AR and may be further improved when combined with additional therapies such as Gemtuzumab Ozogamicin. These findings underline the importance of individualized treatment of pediatric AML.

Citing Articles

Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center.

Kebede A, Garfinkle E, Mathew M, Varga E, Colace S, Wheeler G Front Oncol. 2024; 14:1498409.

PMID: 39687881 PMC: 11647012. DOI: 10.3389/fonc.2024.1498409.

A simplified and robust risk stratification model for stem cell transplantation in pediatric acute myeloid leukemia.

Yang H, Xun Y, Shen Y, Wang H, Tao Y, Wang H Cell Rep Med. 2024; 5(10):101762.

PMID: 39366384 PMC: 11513827. DOI: 10.1016/j.xcrm.2024.101762.

Distinct Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with Mutations: Implications for Targeted Therapy.

Zhao L, Chen H, Lan F, Hao J, Zhang W, Li Y Int J Mol Sci. 2024; 25(17).

PMID: 39273530 PMC: 11395013. DOI: 10.3390/ijms25179581.

Treatment outcomes of pediatrics acute myeloid leukemia (AML) and associated factors in the country's tertiary referral hospital, Ethiopia.

Mamo W, Moges A, Yesuf S, Mohamedsaid A, Arega G BMC Cancer. 2024; 24(1):640.

PMID: 38789952 PMC: 11127368. DOI: 10.1186/s12885-024-12404-5.

ARHGAP4 promotes leukemogenesis in acute myeloid leukemia by inhibiting DRAM1 signaling.

Qi Y, Hu M, Han C, Wang J, Chen F, Guo H Oncogene. 2023; 42(34):2547-2557.

PMID: 37443303 DOI: 10.1038/s41388-023-02770-y.

References

Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999; 93(9):3074-80. View

Zwaan C, Meshinchi S, Radich J, Veerman A, Huismans D, Munske L . FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003; 102(7):2387-94. DOI: 10.1182/blood-2002-12-3627. View

Guest E, Aplenc R, Sung L, Raimondi S, Hirsch B, Alonzo T . Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017; 130(7):943-945. PMC: 5561899. DOI: 10.1182/blood-2017-01-762336. View

Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S . Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Int J Hematol. 2018; 107(5):586-595. DOI: 10.1007/s12185-017-2395-x. View

Meshinchi S . Allelic ratio: a marker of clonal dominance. Blood. 2014; 124(23):3341-2. DOI: 10.1182/blood-2014-10-605048. View

Bolouri H, Farrar J, Triche Jr T, Ries R, Lim E, Alonzo T . The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2017; 24(1):103-112. PMC: 5907936. DOI: 10.1038/nm.4439. View

Tarlock K, Alonzo T, Gerbing R, Raimondi S, Hirsch B, Sung L . Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2015; 22(8):1951-7. PMC: 4834220. DOI: 10.1158/1078-0432.CCR-15-1349. View

Stirewalt D, Kopecky K, Meshinchi S, Appelbaum F, Slovak M, Willman C . FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001; 97(11):3589-95. DOI: 10.1182/blood.v97.11.3589. View

Linch D, Hills R, Burnett A, Khwaja A, Gale R . Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood. 2014; 124(2):273-6. DOI: 10.1182/blood-2014-02-554667. View

10.

Stirewalt D, Pogosova-Agadjanyan E, Tsuchiya K, Joaquin J, Meshinchi S . Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML. Blood Cancer J. 2014; 4:e208. PMC: 4042297. DOI: 10.1038/bcj.2014.27. View

11.

Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J . Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol. 1999; 33(6):525-9. DOI: 10.1002/(sici)1096-911x(199912)33:6<525::aid-mpo1>3.0.co;2-8. View

12.

Hasle H . A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol. 2014; 166(1):23-33. DOI: 10.1111/bjh.12900. View

13.

Patnaik M . The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2017; 59(10):2273-2286. DOI: 10.1080/10428194.2017.1399312. View

14.

Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I . Prognostic impact of low allelic ratio ITD and mutation in acute myeloid leukemia. Blood Adv. 2018; 2(20):2744-2754. PMC: 6199656. DOI: 10.1182/bloodadvances.2018020305. View

15.

Dohner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson R . Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2019; 135(5):371-380. PMC: 6993016. DOI: 10.1182/blood.2019002697. View

16.

Meshinchi S, Woods W, Stirewalt D, Sweetser D, Buckley J, Tjoa T . Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001; 97(1):89-94. DOI: 10.1182/blood.v97.1.89. View

17.

Yunus N, Johan M, Al-Jamal H, Husin A, Hussein A, Hassan R . Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia. Asian Pac J Cancer Prev. 2015; 16(12):4869-72. DOI: 10.7314/apjcp.2015.16.12.4869. View

18.

Kottaridis P, Gale R, Frew M, Harrison G, Langabeer S, BELTON A . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the.... Blood. 2001; 98(6):1752-9. DOI: 10.1182/blood.v98.6.1752. View

19.

Meshinchi S, Alonzo T, Stirewalt D, Zwaan M, Zimmerman M, Reinhardt D . Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006; 108(12):3654-61. PMC: 1895470. DOI: 10.1182/blood-2006-03-009233. View

20.

Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K . Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997; 11(9):1447-52. DOI: 10.1038/sj.leu.2400756. View